BioXcel Therapeutics (BTAI) Other Non-Current Liabilities (2022 - 2026)
BioXcel Therapeutics (BTAI) posted quarterly Other Non-Current Liabilities of $6.7 million for Q1 2026, up 105.13% year-over-year from $3.3 million in Q1 2025, and up 275.2% quarter-over-quarter from $1.8 million in Q4 2025.
BioXcel Therapeutics (BTAI) Other Non-Current Liabilities (2022 - 2026) Analysis & Trends
BioXcel Therapeutics' Other Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $6.7 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 105.13% year-over-year to $6.7 million; the TTM figure through Mar 2026 stood at $6.7 million (up 105.13% YoY), while the FY2025 annual figure was $1.8 million, down 73.01% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $6.7 million, up from $1.8 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $21.2 million in Q1 2024, with the low at $1.8 million in Q4 2025.
- The 5-year median for Other Non-Current Liabilities is $2.6 million (2023), against an average of $4.6 million.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities surged 724.48% in 2024, then sank 84.57% in 2025.
- BioXcel Therapeutics' Other Non-Current Liabilities stood at $2.3 million in 2022, then slipped by 18.69% to $1.9 million in 2023, then jumped by 248.19% to $6.6 million in 2024, then slumped by 73.01% to $1.8 million in 2025, then jumped by 275.2% to $6.7 million in 2026.
- Business Quant data shows BTAI's Other Non-Current Liabilities at $6.7 million in Q1 2026, $1.8 million in Q4 2025, and $3.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | BioXcel Therapeutics | 24.29 Mn | 24.29 Mn | 160,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.11 Mn |
| Mar 31, 2026 | 6.72 Mn |
| Dec 31, 2025 | 1.79 Mn |
| Sep 30, 2025 | 3.61 Mn |
| Jun 30, 2025 | 2.61 Mn |
| Mar 31, 2025 | 3.27 Mn |
| Dec 31, 2024 | 6.63 Mn |
| Sep 30, 2024 | 4.37 Mn |
| Jun 30, 2024 | 9.19 Mn |
| Mar 31, 2024 | 21.22 Mn |
| Dec 31, 2023 | 1.91 Mn |
| Sep 30, 2023 | 2.03 Mn |
| Jun 30, 2023 | 2.03 Mn |
| Mar 31, 2023 | 2.57 Mn |
| Dec 31, 2022 | 2.34 Mn |
| Sep 30, 2022 | 1.89 Mn |
| Jun 30, 2022 | 1.95 Mn |